Interestingly, in pediatric cancers, M2 expression of PD-L1 has been shown to be extremely low to non-existent, which may explain why current PD-1/PD-L1 immunotherapies demonstrate mixed results [312,326,327,328]. Here, CD274 is linked to childhood malignant neoplasm.